NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY – Get Free Report) shares crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $0.00 and traded as high as $0.62. NovaBay Pharmaceuticals shares last traded at $0.62, with a volume of 87,443 shares.
NovaBay Pharmaceuticals Price Performance
The company has a market capitalization of $2.65 million, a P/E ratio of -0.06 and a beta of 2.82.
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($1.37) earnings per share (EPS) for the quarter. The firm had revenue of $2.40 million during the quarter. NovaBay Pharmaceuticals had a negative return on equity of 146.20% and a negative net margin of 79.70%. Equities analysts forecast that NovaBay Pharmaceuticals, Inc. will post -2.54 earnings per share for the current year.
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health.
See Also
- Five stocks we like better than NovaBay Pharmaceuticals
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Is Spotify Stock Poised to Soar? Options Traders Think So
- When to Sell a Stock for Profit or Loss
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Stock Dividend Cuts Happen Are You Ready?
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.